Prognostic value of LIPC in non-small cell lung carcinoma

Cell Cycle

Volumn 12, Issue 4, 2013, Pages 647-654

  Galluzzi, Lorenzo ^a,b   Goubar, Aicha ^a,c   Ken Andre Olaussen ^a,c,d   Vitale, Ilio ^a,e   Senovilla, Laura ^a,e   Michels, Judith ^a,d,e   Angelique Robin ^a,c   Dorvault, Nicolas ^a,c   Besse, Benjamin ^a,f   Validire, Pierre ^g   Fouret, Pierre ^e,h,i   Behrens, Carmen ^j   Wistuba, Ignacio Ivan ^j   Soria, Jean Charles ^a,c,f   Kroemer, Guido ^b,e,f,k,l  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Universite Paris Sud   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e INSERM   (France)

^f IGR   (France)

^g INSTITUT MUTUALISTE MONTSOURIS   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l CENTRE DE RECHERCHE DES CORDELIERS   (France)

more..

Author keywords

Anaplastic lymphoma kinase; Apoptosis; PDXP; Personalized medicine; Pyridoxine

Indexed keywords

CISPLATIN; LIVER TRIACYLGLYCEROL LIPASE; PYRIDOXAL KINASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION;

EID: 84874614098     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.23517     Document Type: Article

References (33)

1. Beers MH. Lung carcinoma. In: Porter RS, Jones TV, eds. The Merck manual of diagnosis and therapy. Rahway: Merck & Co., Inc., 2008:2992
2. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100:1672-94; PMID:19033571; http://dx.doi.org/10.1093/jnci/djn389
3. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7:573-84; PMID:17625587; http://dx.doi.org/10.1038/nrc2167
4. Köberle B, Tomicic MT, Usanova S, Kaina B. Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 2010; 1806:172-82; PMID:20647037
5. Winter C, Albers P. Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 2011; 7:43-53; PMID:21116298; http://dx.doi. org/10.1038/nrendo.2010.196
6. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869-83; PMID:21892204; http://dx.doi.org/10.1038/onc.2011.384
7. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-79; PMID:14576837; http://dx.doi.org/10.1038/ sj.onc.1206933
8. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010; 9:447-64; PMID:20467424; http://dx.doi. org/10.1038/nrd3137
9. Galluzzi L, Larochette N, Zamzami N, Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006; 25:4812-30; PMID:16892093; http://dx.doi.org/10.1038/sj.onc.1209598
10. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011; 10:221-37; PMID:21358741; http://dx.doi.org/10.1038/nrd3373
11. La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 2011; 8:587-96; PMID:21862978; http://dx.doi.org/10.1038/nrclinonc.2011.121
12. Brower V. Biomarkers: Portents of malignancy. Nature 2011; 471:S19-21; PMID:21430715; http://dx.doi. org/10.1038/471S19a
13. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39; PMID:15118073; http://dx.doi.org/10.1056/NEJMoa040938
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32; PMID:16014882; http://dx.doi.org/10.1056/NEJMoa050753
15. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133-44; PMID:16014883; http://dx.doi. org/10.1056/NEJMoa050736
16. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561-6; PMID:17625570; http://dx.doi.org/10.1038/ nature05945
17. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al.; IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-91; PMID:16957145; http://dx.doi. org/10.1056/NEJMoa060570
18. Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012; 2:257-69; PMID:22854025; http://dx.doi.org/10.1016/j.celrep. 2012.06.017
19. Galluzzi L, Vitale I, Senovilla L, Eisenberg T, Carmona-Gutierrez D, Vacchelli E, et al. Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle 2012; 11:3472-80; PMID:22918244; http://dx.doi.org/10.4161/cc.21789
20. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010; 70:1793-803; PMID:20145152; http://dx.doi. org/10.1158/0008-5472.CAN-09- 3112
21. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al.; Nomenclature Committee on Cell Death 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16:3-11; PMID:18846107; http://dx.doi. org/10.1038/cdd.2008. 150
22. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19:107-20; PMID:21760595; http://dx.doi.org/10.1038/cdd.2011.96
23. Haraguchi M, Torii S, Matsuzawa Si, Xie Z, Kitada S, Krajewski S, et al. Apoptotic protease activating factor 1 (Apaf-1)-independent cell death suppression by Bcl-2. J Exp Med 2000; 191:1709-20; PMID:10811864; http://dx.doi.org/10.1084/jem.191.10.1709
24. Zermati Y, Mouhamad S, Stergiou L, Besse B, Galluzzi L, Boehrer S, et al. Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. Mol Cell 2007; 28:624-37; PMID:18042457; http://dx.doi.org/10.1016/j.molcel. 2007.09.030
25. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nuñez G, Castle VP. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 1995; 55:2576-82; PMID:7780971
26. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87:99-163; PMID:17237344; http://dx.doi. org/10.1152/physrev.00013.2006
27. Semenkovich CF, Chen SH, Wims M, Luo CC, Li WH, Chan L. Lipoprotein lipase and hepatic lipase mRNA tissue specific expression, developmental regulation, and evolution. J Lipid Res 1989; 30:423-31; PMID:2723548
28. González-Navarro H, Nong Z, Freeman L, Bensadoun A, Peterson K, Santamarina-Fojo S. Identification of mouse and human macrophages as a site of synthesis of hepatic lipase. J Lipid Res 2002; 43:671-5; PMID:11971936
29. Stinchcombe TE, Socinski MA. Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy. Nat Rev Clin Oncol 2010; 7:426-8; PMID:20668478; http://dx.doi.org/10.1038/nrclinonc.2010.99
30. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 2007; 67:6253-62; PMID:17616683; http://dx.doi.org/10.1158/0008-5472.CAN-07- 0538
31. Vitale I, Senovilla L, Jemaà M, Michaud M, Galluzzi L, Kepp O, et al. Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. EMBO J 2010; 29:1272-84; PMID:20186124; http://dx.doi. org/10.1038/emboj. 2010.11
32. Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, et al. Erlotinib exhibits antineoplastic offtarget effects in AML and MDS: a preclinical study. Blood 2008; 111:2170-80; PMID:17925489; http://dx.doi.org/10. 1182/blood-2007-07-100362
33. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, et al. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Dis 2010; 1:e10; PMID:21364612; http://dx.doi. org/10.1038/cddis.2009.8